The Lancet has an article about the effects of SAR
Post# of 147782
(Total Views: 632)
Posted On: 03/23/2022 10:19:44 AM
The Lancet has an article about the effects of SARS-CoV-2 on prenatal lung growth. Perhaps a future trial could study Leronlimab for pregnant women. The list of opportunities for Leronlimab (as well as mankind) continue to grow as more is discovered about the long-term impacts of Covid. Here are some excerpts.
We used fetal MRI to assess lung volume as a measure of pulmonary growth in the offspring of women with uncomplicated SARS-CoV-2 infection during pregnancy.
We analysed the MRI data of 34 pregnant women (median gestational age 33·5 weeks [range 24–40] with only mild symptoms of PCR-proven SARS-CoV-2 infection and no related hospital admissions. Fetal lung volume, normalised to estimated fetal weight, was described as a percentage of the respective 50th percentile reference values. The effects of gestational age at MRI scan, sex, timepoint (trimester) of infection (confirmed by positive PCR), and duration of infection in days (PCR to MRI) on fetal lung volume were assessed by generalised linear modelling with identity link function for normal distribution.
In pregnant women who tested positive for SARS-CoV-2, normalised fetal lung volume was significantly reduced compared with age-adjusted reference values in the absence of structural abnormalities or organ infarction, and was unexplained by differences in somatic growth. The timepoint of infection showed significant effects on fetal lung growth, with reduced lung volumes observed with SARS-CoV-2 infections acquired during the third trimester (69% vs 91% of 50th percentile reference in the first or second trimester). Duration of infection (p=0·5657), gestational age at MRI scan (p=0·5704), and sex (p=0·3721) did not show significant effects.
The effects of SARS-CoV-2 infection during pregnancy on fetal lung development have been largely understudied throughout the COVID-19 pandemic. To our knowledge, this is the first study showing reduced fetal lung volume in otherwise healthy pregnant women with SARS-CoV-2 infection.
https://www.thelancet.com/journals/lanres/art...1/fulltext
We used fetal MRI to assess lung volume as a measure of pulmonary growth in the offspring of women with uncomplicated SARS-CoV-2 infection during pregnancy.
We analysed the MRI data of 34 pregnant women (median gestational age 33·5 weeks [range 24–40] with only mild symptoms of PCR-proven SARS-CoV-2 infection and no related hospital admissions. Fetal lung volume, normalised to estimated fetal weight, was described as a percentage of the respective 50th percentile reference values. The effects of gestational age at MRI scan, sex, timepoint (trimester) of infection (confirmed by positive PCR), and duration of infection in days (PCR to MRI) on fetal lung volume were assessed by generalised linear modelling with identity link function for normal distribution.
In pregnant women who tested positive for SARS-CoV-2, normalised fetal lung volume was significantly reduced compared with age-adjusted reference values in the absence of structural abnormalities or organ infarction, and was unexplained by differences in somatic growth. The timepoint of infection showed significant effects on fetal lung growth, with reduced lung volumes observed with SARS-CoV-2 infections acquired during the third trimester (69% vs 91% of 50th percentile reference in the first or second trimester). Duration of infection (p=0·5657), gestational age at MRI scan (p=0·5704), and sex (p=0·3721) did not show significant effects.
The effects of SARS-CoV-2 infection during pregnancy on fetal lung development have been largely understudied throughout the COVID-19 pandemic. To our knowledge, this is the first study showing reduced fetal lung volume in otherwise healthy pregnant women with SARS-CoV-2 infection.
https://www.thelancet.com/journals/lanres/art...1/fulltext
(4)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼